Kodiak Sciences Inc (KOD) Stock Price, Quote & News

Company Profile

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that has complete Phase 3 clinical study to treat high prevalence retinal vascular diseases; and in Phase 3 clinical study for the treatment of diabetic retinopathy, wet age-related macular degenerati...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 281 0850

Website: kodiak.com

Address:

1200 Page Mill Road, Palo Alto, United States

Cutlass Oct. 24 at 9:08 PM

$KOD . . . and a Good Week +32% ✅

0 · Reply

spinusn27 Oct. 24 at 8:42 PM

$KOD good day today. Gap filled the open and closed nicely. Have a great weekend 😀

0 · Reply

AStrokeOfLuck Oct. 24 at 1:18 PM

$KOD

0 · Reply

Cutlass Oct. 24 at 12:05 PM

$KOD 👀

0 · Reply

erevnon Oct. 24 at 11:08 AM

JP Morgan upgrades Kodiak Sciences $KOD from Neutral to Overweight and raises the price target from $15 to https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

JarvisFlow Oct. 24 at 10:30 AM

JP Morgan updates rating for Kodiak Sciences ( $KOD ) to Overweight, target set at 15 → 24.

0 · Reply

notreload_ai Oct. 24 at 9:42 AM

JPMorgan raises $KOD rating to Overweight with $24 price target, citing reduced risk for KSI-101 drug treating eye inflammation and swelling. https://notreload.xyz/jpmorgan-upgrades-kodiak-sciences-ksi-101-potential/

0 · Reply

JarvisFlow Oct. 23 at 9:49 PM

LifeSci Capital has adjusted their stance on Kodiak Sciences ( $KOD ), setting the rating to Outperform with a target price of 40.

0 · Reply

Stekli27 Oct. 21 at 8:17 PM

$KOD Nostradamus 😋

0 · Reply

Cutlass Oct. 21 at 6:45 PM

$KOD Very - 400% and holding

0 · Reply

New data for Kodiak's KSI-101 from the APEX study reinforce its clinically meaningful vision gains and rapid retinal drying in macular edema secondary to inflammation (MESI)

Sep 2, 2025, 8:00 AM EDT - 7 weeks ago

Kodiak Sciences to Participate in Upcoming Scientific Conferences Highlighting KSI-101 in Patients with Macular Edema Secondary to Inflammation (MESI)

Aug 27, 2025, 10:40 AM EDT - 2 months ago

Harbour BioMed Reports 2025 Interim Results

Aug 27, 2025, 6:54 AM EDT - 2 months ago

Jim Cramer: Kodiak Sciences Is A 'Pure Spec' Stock, Recommends Buying This Utilities Stock

Aug 19, 2025, 2:18 PM EDT - 2 months ago

Kodiak Sciences to Present at American Chemical Society Fall 2025

Aug 13, 2025, 4:00 PM EDT - 2 months ago

Kodiak Sciences Announces Recent Business Highlights and Second Quarter 2025 Financial Results

Jul 10, 2025, 8:00 AM EDT - 3 months ago

Kodiak Sciences to Host Investor R&D Day on July 16, 2025

Jun 25, 2025, 4:45 PM EDT - 4 months ago

Kodiak Sciences to Present KSI-101 Highlights at 2025 Congress of the International Ocular Inflammation Society

May 29, 2025, 9:32 PM EDT - 5 months ago

Kodiak Sciences to Present at 2025 Jefferies Global Healthcare Conference

May 14, 2025, 4:15 PM EDT - 5 months ago

Kodiak Sciences Announces Recent Business Highlights and First Quarter 2025 Financial Results

May 1, 2025, 11:43 PM EDT - 6 months ago

Kodiak Sciences Data at ARVO 2025 Highlight Power and Versatility of ABC Platform in Addressing Complex Multifactorial Ocular Diseases

Mar 27, 2025, 4:01 PM EDT - 7 months ago

Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results

Mar 10, 2025, 4:39 PM EDT - 8 months ago

Kodiak Sciences Completes Enrollment in Second Registrational Trial of Tarcocimab in Patients with Diabetic Retinopathy

Feb 23, 2025, 8:08 PM EST - 8 months ago

Kodiak Sciences: Anti-VEGF Could Win Nicely On Retinal Disorders

Feb 4, 2025, 7:30 AM EST - 9 months ago

Kodiak Sciences to Present at Glaucoma 360 New Horizons Forum 2025

Jan 7, 2025, 6:00 AM EST - 10 months ago

Kodiak Sciences to Present at 43rd Annual J.P. Morgan Healthcare Conference

Dec 9, 2024, 12:33 PM EST - 11 months ago

Eye-Disease Focused Kodiak Sciences Is A Promising 'Turnaround Story For 2025': Analyst Upgrades Stock

Nov 14, 2024, 4:01 PM EST - 1 year ago

Kodiak Sciences Announces Recent Business Highlights and Third Quarter 2024 Financial Results

Nov 11, 2024, 6:15 AM EST - 1 year ago

Kodiak Sciences to Participate in Upcoming Investor Conferences

Oct 14, 2024, 5:35 PM EDT - 1 year ago

Kodiak Sciences to Present at Innovate Retina 2024

Sep 23, 2024, 6:00 AM EDT - 1 year ago

Kodiak Sciences to Host Investor R&D Day Today at 10:30am Eastern Time

Sep 17, 2024, 4:05 PM EDT - 1 year ago

Kodiak Sciences to Host Investor R&D Day on September 23, 2024 in New York City

Aug 14, 2024, 4:01 PM EDT - 1 year ago

Kodiak Sciences Announces Recent Business Highlights and Second Quarter 2024 Financial Results

May 29, 2024, 4:36 PM EDT - 1 year ago

Kodiak Sciences to Present at Upcoming Investor and Clinical Conferences

May 15, 2024, 4:01 PM EDT - 1 year ago

Kodiak Sciences Announces Recent Business Highlights and First Quarter 2024 Financial Results

May 13, 2024, 7:32 PM EDT - 1 year ago

Kodiak Sciences Announces Treatment of First Patients in Phase 3 GLOW2 Study of Tarcocimab Tedromer in Diabetic Retinopathy

May 2, 2024, 4:30 PM EDT - 1 year ago

Kodiak Sciences Data at ARVO 2024 Highlight Depth of Early and Late-Phase Retina Pipeline including Advancements with High Drug-Antibody-Ratio Therapeutics Built on Kodiak's Antibody Biopolymer Conjugate (ABC) Platform

Mar 28, 2024, 8:57 PM EDT - 1 year ago

Kodiak Sciences Inc. (KOD) Q4 2023 Earnings Call Transcript

Mar 28, 2024, 6:30 AM EDT - 1 year ago

Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results

Mar 26, 2024, 6:15 AM EDT - 1 year ago

Kodiak Sciences to Report Fourth Quarter and Full-Year 2023 Financial Results and Host Business Updates Webcast on March 28, 2024

Jan 30, 2024, 6:30 AM EST - 1 year ago

Kodiak Sciences Announces Upcoming Presentation of First Time Results of KSI-501ABC Phase 1 Study at the Angiogenesis, Exudation, and Degeneration 2024 Virtual Meeting

Jan 4, 2024, 4:15 PM EST - 1 year ago

Kodiak Sciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Nov 21, 2023, 4:15 PM EST - 2 years ago

Kodiak Sciences to Present at the 6th Annual Evercore ISI HealthCONx Conference

Nov 14, 2023, 4:01 PM EST - 2 years ago

Kodiak Sciences Announces Third Quarter 2023 Financial Results and Recent Business Highlights

Nov 6, 2023, 5:00 AM EST - 2 years ago

Kodiak reboots tarcocimab tedromer development program following strong positive results in Phase 3 diabetic retinopathy GLOW study and following dialogue with US regulatory authorities on a regulatory pathway for BLA submission

Nov 1, 2023, 11:21 PM EDT - 2 years ago

KODIAK SCIENCES ANNOUNCES FIRST TIME PRESENTATION OF PRIMARY ENDPOINT DATA FROM TARCOCIMAB TEDROMER PHASE 3 GLOW STUDY IN PATIENTS WITH DIABETIC RETINOPATHY AT AMERICAN ACADEMY OF OPHTHALMOLOGY ANNUAL MEETING

Oct 11, 2023, 6:00 AM EDT - 2 years ago

Kodiak Sciences Announces Upcoming Presentations at the 56th Annual Scientific Meeting of the Retina Society

Sep 8, 2023, 6:00 AM EDT - 2 years ago

Kodiak Sciences to Present at the Morgan Stanley 21st Annual Global Healthcare Conference

Sep 7, 2023, 6:00 AM EDT - 2 years ago

New one-year results for Kodiak's tarcocimab tedromer in the pivotal BEACON trial reinforce durability signal and demonstrate matched efficacy and comparable safety and tolerability in retinal vein occlusion

Aug 14, 2023, 4:01 PM EDT - 2 years ago

Kodiak Sciences Announces Second Quarter 2023 Financial Results and Recent Business Highlights

Jul 24, 2023, 6:38 AM EDT - 2 years ago

Kodiak Sciences scraps development of eye disorder drug

Jul 24, 2023, 6:36 AM EDT - 2 years ago

Kodiak Sciences stock plunges into record-low territory after decision to discontinue wet AMD treatment

Jul 24, 2023, 6:00 AM EDT - 2 years ago

Kodiak Sciences Announces Topline Results from its Phase 3 Studies of Tarcocimab Tedromer in Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema and Provides Update on Tarcocimab Development Program

May 30, 2023, 4:15 PM EDT - 2 years ago

Kodiak Sciences to Present at Upcoming Investor Conferences

May 15, 2023, 4:01 PM EDT - 2 years ago

Kodiak Sciences Announces First Quarter 2023 Financial Results and Recent Business Highlights

Apr 21, 2023, 7:30 AM EDT - 2 years ago

Kodiak Sciences Announces Upcoming Presentations on its Product and Research Pipeline at ARVO 2023 Annual Meeting

Apr 3, 2023, 7:30 AM EDT - 2 years ago

Kodiak Sciences Expands Development Pipeline with Treatment of First Patient in Phase 1 Clinical Study of KSI-501, an Investigational Bispecific Antibody Biopolymer Conjugate for Retinal Diseases

Mar 28, 2023, 4:08 PM EDT - 2 years ago

Kodiak Sciences Announces Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights

Feb 9, 2023, 7:30 AM EST - 2 years ago

Kodiak Sciences Announces Upcoming Presentation of KSI-301 (tarcocimab tedromer) Clinical Data and Antibody Biopolymer Conjugate Development Programs at the Angiogenesis, Exudation and Degeneration 2023 Virtual Meeting

Cutlass Oct. 24 at 9:08 PM

$KOD . . . and a Good Week +32% ✅

0 · Reply

spinusn27 Oct. 24 at 8:42 PM

$KOD good day today. Gap filled the open and closed nicely. Have a great weekend 😀

0 · Reply

AStrokeOfLuck Oct. 24 at 1:18 PM

$KOD

0 · Reply

Cutlass Oct. 24 at 12:05 PM

$KOD 👀

0 · Reply

erevnon Oct. 24 at 11:08 AM

JP Morgan upgrades Kodiak Sciences $KOD from Neutral to Overweight and raises the price target from $15 to https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

JarvisFlow Oct. 24 at 10:30 AM

JP Morgan updates rating for Kodiak Sciences ( $KOD ) to Overweight, target set at 15 → 24.

0 · Reply

notreload_ai Oct. 24 at 9:42 AM

0 · Reply

JarvisFlow Oct. 23 at 9:49 PM

LifeSci Capital has adjusted their stance on Kodiak Sciences ( $KOD ), setting the rating to Outperform with a target price of 40.

0 · Reply

Stekli27 Oct. 21 at 8:17 PM

$KOD Nostradamus 😋

0 · Reply

Cutlass Oct. 21 at 6:45 PM

$KOD Very - 400% and holding

0 · Reply

richard52 Oct. 21 at 3:03 PM

$ICU just looking at $KOD I was in it for a while but finally decided that this stock $ICU was where my heart belonged. The chart of KOD will hopefully be ours before too long.

1 · Reply

Cutlass Oct. 21 at 12:41 PM

$KOD Breaks 21 it could fly 👓

1 · Reply

PeaceThanks Oct. 20 at 11:50 PM

$KOD Next $CHRS

0 · Reply

spinusn27 Oct. 20 at 10:59 PM

$KOD follow the money. Baker Brothers and who ever else both the last couple of weeks.

0 · Reply

Cutlass Oct. 20 at 8:05 PM

$KOD +25% today, got gobbled up again 🎁

0 · Reply

geothug Oct. 20 at 6:42 PM

$KOD can someone please explain the bullush fundamentals here? After July 2023 i was pretty sure KOD was dead money. Not sure what I'm missing.

3 · Reply

spinusn27 Oct. 20 at 3:51 PM

$KOD oh

0 · Reply

buylowandwait Oct. 20 at 3:44 PM

$KOD Double digits prediction was too conservative. My new prediction: KOD's ophthalmology asset will propel it to new historical high >150 ! This company hasn't had cash raise for long time, and after cash raise later this year, it will reach record high above 100 on P3 results.

1 · Reply

Cutlass Oct. 20 at 3:30 PM

$KOD My oh my - 👓🧨🎉

0 · Reply

_www_larval_com_ Oct. 20 at 1:39 PM

$ELBM 16%[10%] $RAPT -11%[16%] $VSTM -10%[-15%] $HOND -9%[-6%] $KOD 9%[26%] most notable movement within the first minutes of trading.

0 · Reply

Stekli27 Oct. 20 at 12:30 PM

$KOD

0 · Reply

Stekli27 Oct. 17 at 8:57 AM

$KOD

0 · Reply

Market Cap	903.78M
Revenue (ttm)	0.00
Net Income (ttm)	-176.21M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	1,160,200
Avg Vol	949,140
Day's Range	N/A - N/A
Shares Out	52.82M
Stochastic %K	84%
Beta	2.67
Analysts	Sell
Price Target	$14.60